13:48 August 5, 2025
Introduction
The HIMS & HERS share The focus is currently on investors. After the latest quarterly figures, the paper lost significantly in value – but how serious is the setback really? And much more important: Should you buy HIMS & HERS stocks or wait better? We analyze the current situation of the innovative telemedicine company and examine the opportunities and risks.
► Hims & Hers Health | WKN: A2QMYY | ISIN: US4330001060 | Ticker: HIMS
✅ three key Takeaways
-
📉 sales growth misses expectations-despite strong Yoy numbers:
With a quarter turnover of USD 544.8 million Hims & Hers was able to do the previous year by full +73 % surpassed, but remained Behind the analyst expectations of $ 552 million. The HIMS & HERS share reacted promptly with one Course drop of over 12 % Presidential. -
💸 Winning per share convinced – however, EBITDA disappointing:
The adjusted profit per share was included 17 cents (Expectation: 15 cents) – a plus point. But the EBITDA of USD 60–70 million remains clear Under the consensus of $ 77.1 million – What worries about the margins. -
⚖️ Legal pressure and Novo Nordisk exit share stock:
The end of cooperation with Novo Nordisk Due to legal concerns about dealing with compound GLP-1 preparations such as Pathovy represents another risk factor. The accusation: misleading marketing and regulatory violations.
📊 quarterly in detail – what is behind the decline?
Even if the increase in sales was impressive, analysts are apparently seen A slowdown of growththat does not match the previous success path. The forecast for Q3 lies with USD 570–590 million As part of expectations – however without a positive surprise effect.
Because of these rather caught numbers, there was one striking correction The HIMS & HERS share. She is now approaching one critical support area at 52/53 USDthat results from previous quarter movements and volume profiles.
🚨 regulatory headwind – how big is the danger?
The persistent controversy around GLP-1 compounds How Ozempic alternatives remains an uncertainty factor. Despite official loosening and shortage of offer, the FDA now more restrictivewhat composite medication regards. For HIMS & HERS, this is a potential risk of reputation and business.
The company defends its approach and emphasizes that Individual doses still allowed and available be – if medically justified. Nevertheless, the uncertainty should be further on the HIMS & HERS share load.
📉 Technical location – buy stocks or wait for the reset?
The share is now noted in one critical area around $ 52/53. Should she be there Stabilize and find buyersis a Rebound towards the all -time high at 70 USD possible. If this does not succeed, a relapse could go under 45 USD threaten. For investors who want to buy shares in the long terma soil formation is crucial – otherwise there are further setbacks.
🧠 Conclusion: HIMS & HERS share in the twilight – wait or bare?
The HIMS & HERS share stands at a turning point. Strong growth, new markets and innovative telemedicine offers speak in the long term For the company. In the short term, however, dominate Uncertainty and regulatory pressure. If you want to buy shares now, you should Pay attention to technical stabilization and regulatory clarity – Then the entry could be worthwhile. Until then: Observe watch instead of blind.
HIMS & HERS share Chart analysis – Daily:
Source: XStation55 by XTB, recorded on 05.08.2025. Time history according to the information directly in the chart. Past results are not an indicator of future performance. The trade instrument is noted in USD. Possible currency fluctuations can affect the return.
SHARES Coming free of commission plus a free stock for new customers:
-
Shares worldwide commission -free* act with XTB!
-
Get a free cactic for new customers as an action now
-
Details and conditions of participation About the link
Disclosure in accordance with Section 80 WPHG for possible conflicts of interest
The author (m/f/d) can be invested in the securities or basic values discussed.
The authors of the publications write that information at their own risk. Analyzes and assessments are not written in relation to specific investment goals and needs of certain people. Publications of XTB that comment on certain situations on the financial markets and general statements by XTB employees with regard to the financial markets no advice of the customer through XTB and cannot be interpreted as such. The publication does not constitute an offer or advice, recommendation or request for purchase, sale or keep any financial system. XTB is not obliged to update, change or complement the information in this marketing announcement if a statement, assessment, idea or forecast contained in this publication, changes or becomes incorrect. XTB is not liable for losses that have arisen directly or indirectly by making decisions in relation to the content of the publications.
Value developments of trade values from the past are not a reliable indicator of value developments in the future!
The information provided does not contain any cost consideration such as transaction costs, conversion costs or spreads. Such costs can be incurred and the results influence. The return can increase or decrease due to currency fluctuations if the information is based on numbers that are on a different currency than the official currency of the country in which the investor or potential investor is based or in which currency the trading account is conducted.
XTB SA (including branches) is not a tax advisor and does not check whether an investment decision is cheap for customers. Tax treatment depends on the personal circumstances of a customer and can be subject to changes in the future. Courses or the value of a financial instrument can increase and fall.
Risk instructions for CFD
CFD are complex instruments and, because of the leverage effect, contain a high risk of losing money quickly. 71% of small investor accounts lose money from CFD trading with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. An investment and profits from the past guarantee no success in the future. Content, newsletter and communications from XTB do not represent investment advice. The communications are as Advertising to understand.